Rocket Pharmaceuticals, Inc. (RCKT)
Develops gene therapies to treat rare genetic diseases by fixing faulty DNA
$3.22-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+7.5%
The outlook
RCKT is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, reflecting bearish near-term momentum. Analyst coverage shows an average price target roughly 192% above the current price, though this wide gap reflects significant disagreement about fair value. The overall sentiment leans bearish based on current technicals.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +192% vs current price
Analyst price target
~12-month · 11 analysts$9.39average target+192.0% vs now
Now $3.22
Low $3.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$351.1M
52-wk high
$5.45
52-wk low
$2.53
50-day avg
$3.26
200-day avg
$3.59
Trailing P/E
—